Pharma

Sanofi’s 16% of sales is at risk

Posted on Updated on

French drug-maker Sanofi faces risk to its 16% of revenues after its top-selling drug Lantus came under threat from the generic manufacturers. The fear of losing revenue from Lantus has forced Sanofi to defend its intellectual property rights. Recent news flow showed that the maker of Lantus drug filed several patent infringement suits against the generic manufacturers.

Lantus, an “Insulin glargine” (a long-acting basal insulin analogue), accounted for 16.4% of Sanofi’s net sales in 2016. Lantus consists of microcrystals, which slowly releases insulin over a period of 24 hours with a peak-less profile. This drug helps in controlling the blood sugar of diabetic people.

Lantus is one of the major drugs in the anti-diabetic segment. In 2015, Lantus accounted for ~17% of the global sales for anti-diabetic products.

Read the rest of this entry »

Heckyl’s Social Media Heatmap helps beat the Indian Market Mayhem

Posted on Updated on

tweetGlobal jitters headed by China on concerns of economic slowdown in the world’s fastest growing economy , led to tremors in the financial markets across the globe. China’s equity market went through a roller-coaster ride in the last six months touching a peak of 5122 on June 6, surging 66 percent in a very short span of time. The stock market bubble finally busted and the index closed near 3000, losing over 40 percent in last three months.

Read the rest of this entry »